Bishop Rock Capital L.P. cut its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 64.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,192 shares of the company’s stock after selling 25,201 shares during the period. Henry Schein makes up approximately 0.8% of Bishop Rock Capital L.P.’s investment portfolio, making the stock its 25th biggest position. Bishop Rock Capital L.P.’s holdings in Henry Schein were worth $1,164,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Intrust Bank NA lifted its stake in Henry Schein by 1.1% during the second quarter. Intrust Bank NA now owns 1,219 shares of the company’s stock valued at $223,000 after purchasing an additional 13 shares during the last quarter. Bronfman E.L. Rothschild L.P. lifted its stake in Henry Schein by 4.0% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 14,859 shares of the company’s stock valued at $2,719,000 after purchasing an additional 566 shares during the last quarter. Bradley Foster & Sargent Inc. CT lifted its stake in Henry Schein by 2.1% during the second quarter. Bradley Foster & Sargent Inc. CT now owns 33,106 shares of the company’s stock valued at $6,059,000 after purchasing an additional 690 shares during the last quarter. Steinberg Global Asset Management lifted its stake in Henry Schein by 100.0% during the third quarter. Steinberg Global Asset Management now owns 19,412 shares of the company’s stock valued at $1,592,000 after purchasing an additional 9,706 shares during the last quarter. Finally, Comerica Bank lifted its stake in Henry Schein by 10.6% during the second quarter. Comerica Bank now owns 21,833 shares of the company’s stock valued at $4,054,000 after purchasing an additional 2,101 shares during the last quarter. Institutional investors and hedge funds own 91.75% of the company’s stock.

In related news, Director Barry J. Alperin sold 5,796 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $70.76, for a total value of $410,124.96. Following the completion of the sale, the director now owns 48,172 shares in the company, valued at approximately $3,408,650.72. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.19% of the stock is currently owned by corporate insiders.

Shares of Henry Schein, Inc. (NASDAQ HSIC) opened at $67.58 on Thursday. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.55 and a quick ratio of 0.86. The company has a market cap of $11,159.46, a P/E ratio of 19.94, a P/E/G ratio of 2.00 and a beta of 0.99. Henry Schein, Inc. has a 12-month low of $65.28 and a 12-month high of $93.50.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Monday, November 6th. The company reported $0.87 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.90 by ($0.03). The firm had revenue of $3.16 billion during the quarter, compared to analysts’ expectations of $3.05 billion. Henry Schein had a net margin of 4.52% and a return on equity of 19.71%. The firm’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.84 EPS. research analysts forecast that Henry Schein, Inc. will post 3.6 earnings per share for the current year.

Henry Schein announced that its board has initiated a share repurchase program on Monday, September 18th that authorizes the company to repurchase $400.00 million in shares. This repurchase authorization authorizes the company to buy up to 6.3% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s leadership believes its shares are undervalued.

Several analysts recently commented on the stock. Morgan Stanley lowered shares of Henry Schein from an “equal weight” rating to an “underweight” rating and set a $88.00 target price for the company. in a research note on Wednesday. Credit Suisse Group reissued a “neutral” rating and set a $80.00 target price (down from $87.50) on shares of Henry Schein in a research note on Tuesday, November 28th. Stephens assumed coverage on shares of Henry Schein in a research note on Tuesday, November 28th. They set an “equal weight” rating and a $76.00 target price for the company. Zacks Investment Research lowered shares of Henry Schein from a “hold” rating to a “sell” rating in a research note on Monday, November 13th. Finally, TheStreet downgraded shares of Henry Schein from a “b” rating to a “c+” rating in a research report on Monday, November 6th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the company. Henry Schein currently has a consensus rating of “Hold” and an average target price of $88.36.

ILLEGAL ACTIVITY WARNING: This piece of content was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/07/henry-schein-inc-hsic-stake-lessened-by-bishop-rock-capital-l-p.html.

Henry Schein Company Profile

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Institutional Ownership by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.